Danny Wright

Learn More
Rift Valley Fever virus (RVFV) causes recurrent outbreaks of acute life-threatening human and livestock illness in Africa and the Arabian Peninsula. No licensed vaccines are currently available for humans and those widely used in livestock have major safety concerns. A 'One Health' vaccine development approach, in which the same vaccine is co-developed for(More)
BACKGROUND The need for a highly efficacious vaccine against Plasmodium falciparum remains pressing. In this controlled human malaria infection (CHMI) study, we assessed the safety, efficacy and immunogenicity of a schedule combining 2 distinct vaccine types in a staggered immunization regimen: one inducing high-titer antibodies to circumsporozoite protein(More)
Background: The need for a highly efficacious vaccine against Plasmodium falciparum remains pressing. In this controlled human malaria infection (CHMI) study, we assessed the safety, efficacy and immunogenicity of a schedule combining two distinct vaccine types in a staggered immunization regimen: one inducing hightiter antibodies to CSP (RTS,S/AS01B) and(More)
Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of control measures. If the goal of elimination is to be achieved, additional control measures including an effective and durable vaccine will be required. Studies utilising the prime-boost approach to deliver viral vectors encoding the pre-erythrocytic antigen ME-TRAP(More)
slices, the 3D reconstruction technique was done by manual segmentation using the Winsurf software to obtain a vectorial model of the structures of interest: Skin, bones, muscles, nerves, arteries, and veins. Results: In all fetuses, we found a big axial vein in each side, accompanying the sciatic nerve, suggesting that it is the main vein of the thigh at(More)
Background While malaria transmission is falling in many areas due to increased use of bed-nets and anti-malarials, it remains an enormous burden [1]. The leading malaria vaccine candidate, RTS,S, results in often considerably less than 60% efficacy against clinical malaria [2] resulting in a need for other approaches that may enhance this partial(More)
The use of viral vectors in heterologous prime-boost regimens to induce potent T cell responses in addition to humoral immunity is a promising vaccination strategy in the fight against malaria. We conducted an open-label, first-in-human, controlled Phase I study evaluating the safety and immunogenicity of Matrix-M adjuvanted vaccination with a chimpanzee(More)
BACKGROUND The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 11,000 deaths. The development of an effective Ebola vaccine is a priority for control of a future outbreak. METHODS In this phase 1 study, we administered a single dose of the chimpanzee adenovirus 3 (ChAd3) vaccine encoding the surface glycoprotein of(More)
  • 1